Albert Kim

Albert M. Kim, MD, PhD, FACC, FHRS, is an accomplished physician-scientist with expertise in cardiovascular disease, novel therapeutic product development, translational science, and clinical medicine with over two decades of professional experience.

He was most recently a Venture Partner at RA Ventures (Raven) and Chief Medical Officer of the Raven Blackbird Development Team and previously served as Chief Medical Officer of Cytel. Dr. Kim has held senior leadership roles at Novartis and Pfizer, where he oversaw early- and late-stage clinical development programs in cardiometabolic diseases, non-alcoholic steatohepatitis, diabetes, obesity, heart failure, and cachexia. At Pfizer, he served as Vice President, Clinical Research Head for the Internal Medicine Research Unit, overseeing clinical research efforts for the legacy neuroscience portfolio and cardiometabolic diseases, including non-alcoholic steatohepatitis, diabetes, obesity, heart failure, and cachexia. 

Earlier in his career, Dr. Kim worked at the United States Food and Drug Administration’s Division of Cardiac Devices as a medical reviewer and held academic appointments in the VA Boston Cardiac Electrophysiology Section, at Boston University, and Harvard Medical School. Dr. Kim is a Fellow of the American College of Cardiology and the Heart Rhythm Society. He earned his undergraduate degree in biomedical engineering from Harvard University, his MD and PhD from the University of California, Los Angeles, and trained at Brigham and Women's Hospital, Massachusetts General Hospital, and the University of California, San Francisco.